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Summary 
Background 
Cancer is a major cause of death in children worldwide, and the recorded incidence tends to 
increase with time. Internationally comparable data on childhood cancer incidence in the past two 
decades are scarce. This study aimed to provide internationally comparable local data on the 
incidence of childhood cancer to promote research of causes and implementation of childhood 
cancer control. 
Methods 
This population-based registry study, devised by the International Agency for Research on Cancer 
in collaboration with the International Association of Cancer Registries, collected data on all 
malignancies and non-malignant neoplasms of the CNS diagnosed before age 20 years in 
populations covered by high-quality cancer registries with complete data for 2001–10. Incidence 
rates per million person-years for the 0–14 years and 0–19 years age groups were age-adjusted 
using the world standard population to provide age-standardised incidence rates (WSRs), using the 
age-specific incidence rates (ASR) for individual age groups (0–4 years, 5–9 years, 10–14 years, 
and 15–19 years). All rates were reported for 19 geographical areas or ethnicities by sex, age group, 
and cancer type. The regional WSRs for children aged 0–14 years were compared with comparable 
data obtained in the 1980s. 
Findings 
Of 532 invited cancer registries, 153 registries from 62 countries, departments, and territories met 
quality standards, and contributed data for the entire decade of 2001–10. 385 509 incident cases in 
children aged 0–19 years occurring in 2·64 billion person-years were included. The overall WSR 
was 140·6 per million person-years in children aged 0–14 years (based on 284 649 cases), and the 
most common cancers were leukaemia (WSR 46·4), followed by CNS tumours (WSR 28·2), and 
lymphomas (WSR 15·2). In children aged 15–19 years (based on 100 860 cases), the ASR was 
185·3 per million person-years, the most common being lymphomas (ASR 41·8) and the group of 
epithelial tumours and melanoma (ASR 39·5). Incidence varied considerably between and within 
the described regions, and by cancer type, sex, age, and racial and ethnic group. Since the 1980s, 
the global WSR of registered cancers in children aged 0–14 years has increased from 124·0 (95% 
CI 123·3–124·7) to 140·6 (140·1–141·1) per million person-years. 
Interpretation 
This unique global source of childhood cancer incidence will be used for aetiological research and 
to inform public health policy, potentially contributing towards attaining several targets of the 
Sustainable Development Goals. The observed geographical, racial and ethnic, age, sex, and 
temporal variations require constant monitoring and research. 
Introduction 
Cancers rarely occur before age 20 years, and when they do, they raise a range of medical, 
psychological, ethical, and societal concerns. These distinct types of neoplasms require specific 
treatment paths. Furthermore, the extent of the cancer burden in this young population is unknown 
in many low-income and middle-income countries (LMICs), where data on cancer incidence are not 
collected. Even in the presence of population-based cancer registries, collection of information 
about childhood cancers is often neglected because they represent a small proportion of all cancers, 
additional data sources might be required, and the resulting statistics must be subjected to 
meticulous quality control because they are more sensitive to imprecision or missing information. 
Since the publication of the International Incidence of Childhood Cancer, volume 1 (IICC-1) in 
19881 and IICC-2 in 1998,2 no internationally comparable data on incidence patterns of childhood 
cancer have been published. To address this problem, the International Agency for Research on 
Cancer (IARC), in collaboration with the International Association of Cancer Registries (IACR), 
has coordinated a study to assess the incidence of childhood cancer worldwide, the complete results 
of which will be published in IICC-3. The target age range for IICC-3 is 0–19 years, compared with 
0–14 years in IICC-1 and IICC-2. Inclusion of the 15–19 years age group was motivated by the 
shortage of internationally comparable data in this transition age between childhood and adulthood. 
An age range of 0–19 years was also chosen in previous US and European studies of childhood 
cancer incidence and survival.3, 4 
Research in context 
Evidence before this study 
The worldwide incidence of cancer in children aged 0–14 years was reported in 1988 and 1998 in 
two volumes of the International Incidence of Childhood Cancer (IICC), which described incidence 
patterns in the 1970s and 1980s, respectively. We searched MEDLINE and participating registries 
for studies on the incidence of childhood cancer worldwide, with the search terms “childhood 
cancer”, “registry”, “incidence”, and “population”, in February, 2016, without language or 
publication date restrictions. We found that no globally comparable data on cancer types affecting 
children have been published since IICC-2, and no comparison of incidence patterns in children 
aged 15–19 years has been attempted on a global scale. 
Added value of this study 
This study provides an overview of the incidence of cancer in 2001–10 for children aged 0–19 
years, based on data collected in 153 population-based cancer registries in 62 countries, 
departments, and territories on five continents. In addition to the sex, age, and tumour-specific 
incidence rates for 19 world regions or populations for 2001–10, we report an increase in the 
incidence of neoplasms since the 1980s in children aged 0–14 years. This study updates information 
on cancer incidence in children published almost 20 years ago and adds the first global overview of 
cancer incidence in young people aged 15–19 years. It comprehensively summarises the most recent 
and globally comparable data and presents information per sex, age group, geographical region, and 
tumour type. 
Implications of all the available evidence 
The wealth of information provided by this study constitutes a solid baseline to assess needs and 
define priorities in the area of paediatric oncology, supporting Sustainable Development Goal 3 to 
ensure healthy lives and promote wellbeing for all at all ages. The identified variations in cancer 
incidence according to region, sex, age group, and tumour type will provide a springboard for 
specific aetiological research. The shortage of high-quality local information should stimulate 
formation of new and more accurate data sources. 
Here we provide an overview of the findings of the IICC-3 study, based on a selection of quality-
assured datasets from around the world encompassing information for the complete decade of 
2001–10. The objective of this study was to counteract the difficulties in collecting childhood 
cancer data from relevant data sources and provide globally comparable estimates of cancer 
occurrence in children to aid further research and adapt policy measures. 
Methods 
Study design and data sources 
In this epidemiological, population-based registry study, we invited all population-based cancer 
registries that we identified among the membership of the IACR and from published literature in 
MEDLINE or other published sources, such as annual reports, in any language. The search terms 
used for the literature search were “population”, “childhood cancer”, “incidence”, and “registry”. Of 
the invited registries, we selected only those that had submitted their data and met standard data 
quality criteria. We included only registries covering the entire decade of 2001–10, which 
eliminated some high-quality registries that covered non-overlapping time periods. Analyses for the 
0–14 years age group were based on a larger database (the paediatric dataset) than those for the 0–
19 years age group (general dataset), because the paediatric dataset included data from the 
paediatric cancer registries not collecting data in children older than 15 years and these registries 
tended to have a wider coverage than the cancer registries used in the general dataset (appendix pp 
2–4). 
All malignancies and non-malignant tumours of the CNS diagnosed before age 20 years (before age 
15 years in most of the paediatric cancer registries) in the covered populations in 2001–10 were 
eligible for inclusion. In the USA, non-malignant tumours were only registered from 2004 onwards, 
so they were excluded. The submission from each registry contained cancer and population data, 
information about registration coverage, practices, and data sources, and a short narrative describing 
registry operations. Cancer data included individual records of cases with codes for the following: 
sex; age; date of birth; date of incidence; and tumour sequence (ie, the numerical order of 
occurrence of the neoplasm), site, morphology, behaviour, laterality, and most valid basis of 
diagnosis. The 3rd edition of the International Classification of Diseases for Oncology5 was 
required for coding of the tumour site, morphology, behaviour, multiple primary tumours, and basis 
of diagnosis. Non-conforming coding systems were converted and tumours were classified centrally 
according to the 3rd edition of the International Classification of Childhood Cancer (ICCC-3).6 We 
requested each contributing cancer registry to provide total population counts for each ethnic or 
racial group, calendar year, sex, and year of age in the registration area of their registry. 
Procedures 
All submitted datasets were processed and assessed individually in a rigorous peer-review process. 
The assessment criteria included a range of indicators, including the following: minimum number of 
cases; proportion of cases confirmed from cancer tissue examination (microscopic verification); 
proportion of cases registered from death certificate only; proportion of cases with morphology not 
otherwise specified (ie, cases in the unspecified subgroups of ICCC-3 or those coded by unspecified 
morphology codes such as 8000, 8800, 9800); proportion of cases with an unlikely combination of 
site and morphology, or an unlikely age and tumour type; proportion of rare entities (ie, neoplasms 
that occurred with a frequency of <0·05% in large datasets); proportion of dates of birth and 
incidence that were incomplete; proportion of ages that were imprecise; overall incidence rates; 
proportion of cases and incidence by sex, age group, and tumour type; the stability of rates over 
time; proportion of multiple primary diagnoses; and consistency of population data. All 
questionable records and raised issues were fed back to the contributing registries with a request for 
correction or a response. This iterative process resulted in a marked improvement of the overall 
quality of the data included in the analyses. The improvements included completion of missing 
information, additional years of data, inclusion of information from missed data sources, correction 
of coding errors, improvements in calculation of age, inclusion of non-malignant CNS tumours, 
replacement of population data, and explanation of the questioned patterns. 
Statistical analysis 
We calculated age-specific incidence rates (ASR) for four 5-year age groups (0–4 years, 5–9 years, 
10–14 years, and 15–19 years) as the quotient of the number of cases and the number of person-
years in the respective categories of sex, geographical area, and racial or ethnic group for the 
applicable time period, expressed per million person-years. We defined person-years as the sum of 
the population counts in a specific geographical area surveyed by a registry in each year from 2001 
to 2010, categorised by sex and age and, if relevant, race or ethnicity. In the absence of all required 
details, we estimated the covered population counts by linear interpolation (six registries) or 
extrapolation (three registries) from the data provided by the registries, based on an assumption of 
regular population growth, before calculating rates. The purpose of this study was to make 
comparisons among regions and time periods, so all reported incidence rates for the 0–14 years and 
0–19 years age groups were adjusted via direct standardisation. We calculated age-standardised 
rates (WSRs) as the weighted average of the three age-specific rates (to calculate rates for 0–14 
years) or four age-specific rates (for 0–19 years), using the weights of the world standard 
population7 (appendix p 5). We calculated incidence sex ratios by dividing the incidence in male 
individuals with that in female individuals. 
The results are presented for 19 geographical regions or populations and a combined total; all the 
defined regions are either UN-defined regions8 or an aggregate of UN-defined regions, with the 
exception of North America, for which we present data separately for Canada and the USA, and 
have split data for the USA into five racial or ethnic groups. Within the region of south Asia, 
eligible data were only available from India. The described region definition was also driven by the 
data availability and the sizes of the resulting respective regional datasets. We calculated the 
proportion of the covered population of the world and each region by dividing the included person-
years by the total person-years in 2001–10 by age group, as estimated by the UN in 2015.9 
To compare the incidence rates derived from the paediatric dataset for 2001–10 with those 
published in IICC-2,2 we assigned IICC-2 registry data to the same geographical regions as used in 
this IICC-3 study. We calculated the WSRs and their 95% CIs for children aged 0–14 years. 
Although the target period of IICC-2 was the 1980s, the time periods of the contributing registries 
differed both in length and starting years, because they either followed on from the IICC-1 period or 
they could not provide other years of data. 
Statistical analyses were done using Stata/IC (version 12.1). 
Results 
Of the 532 invited cancer registries, 420 submitted their data and 309 met standard data quality 
criteria. Of those, 153 quality-assured registries from 62 countries, departments, and territories 
contributed data for the entire decade (appendix pp 3–4). Of the 153 included registries, 72 were 
initially unacceptable, but improved through the iterative quality assurance procedure. 
Approximately 11·4% of the world population aged 0–14 years (contributing 18 376 710 144 
person-years) was covered by the registries included in our study, ranging from 1·7% in south Asia 
(India) to 99·4% in North America (table 1). The coverage was slightly less, at 8·9%, for young 
people aged 15–19 years (contributing 6 105 345 342 person-years), with the lowest being 0·8% in 
sub-Saharan Africa. Overall, 385 509 registered cases occurring in 2·64 billion person-years 
contributed to the analyses (Table 1, Table 2). Registration of non-malignant CNS tumours differed 
by registry, and was higher in the paediatric dataset than in the general dataset (Table 1, Table 2). 
The overall WSRs were 140·6 per million person-years in children aged 0–14 years and 155·8 per 
million person-years in those aged 0–19 years (table 2). The ASR in young people aged 15–19 
years was 185·3 per million person-years. 
Incidence rates were slightly higher in boys than in girls (incidence sex ratio was 1·17 in the 0–14 
years age group and 1·14 in the 0–19 years age-group) and varied with age, region, and diagnostic 
group (table 2; appendix p 8). Across all regions, incidence was higher in boys than in girls 
(incidence sex ratio ranged from 1·1 to 1·4 in the 0–19 years age group; appendix p 8), except for 
the 15–19 years age group of Native Americans in the USA (incidence sex ratio of 0·9) and in east 
Asia (1·0), where girls had a higher incidence (ratios rounded to one decimal place; appendix p 8). 
The highest incidence sex ratio was observed in the age group of 5–9 years in south Asia (India; 
1·7; appendix p 8). Sex-specific incidence varied by diagnostic group, with renal tumours and 
epithelial tumours more common in girls, with variations by age group (appendix p 8). Germ cell 
and gonadal tumours were also more common in girls than in boys in the 0–14 years age group 
(appendix p 8). 
ASRs were higher in children aged 0–4 years and 15–19 years than in those aged 5–9 years and 10–
14 years (table 2). ASRs also differed between regions, especially for the age groups with high 
ASRs (appendix pp 6, 9). In the 0–14 years group, overall WSRs varied from less than 100 per 
million person-years in sub-Saharan Africa, for Native American children in the USA, and in south 
Asia (India), to more than 150 per million person-years in some subpopulations of North America 
and Europe, and in Oceania (figure 1A; appendix p 6). In young people aged 15–19 years, the 
lowest ASR was observed in south Asia (India), whereas the highest ASRs were seen in some 
predominantly white populations of North America, Europe, and Oceania (figure 1B; appendix p 6). 
The range of tumour types varied markedly with age group (figure 2). In children aged 0–4 years, 
leukaemia represented 36·1% (45 849 of 127 096) of all cases; however, the proportion of 
leukaemia cases was 15·4% (15 520 of 100 860) in young people aged 15–19 years. Conversely, 
lymphomas represented 5·3% (6766 of 127 096) of cases in children aged 0–4 years, and 22·5% 
(22 740 of 100 860) of cases in those aged 15–19 years. CNS tumours were the second most 
frequent tumour type after leukaemia in children aged 0–4 years (21 804 [17·2%] of 127 096), 5–9 
years (19 471 [26·3%] of 74 175), and 10–14 years (16 680 [20·0%] of 83 378; figure 2). Epithelial 
tumours and melanoma represented 0·9% of all cases in children aged 0–4 years (1197 of 127 096), 
but were the second most common tumour group in young people aged 15–19 years (21 480 
[21·3%] of 100 860). 
The most common sympathetic nervous system tumour across all age groups was neuroblastoma. It 
was most frequent in children aged 0–4 years (15 888 [12·5%] of 127 096) and very rare in those 
aged 15–19 years (218 [0·2%] of 100 860; figure 2). Of note is the relatively high sympathetic 
nervous system tumour WSR of 10·2 per million person-years in black children in the USA, which 
contrasts with the WSR of 2·7 per million person-years in the mostly black population of Sub-
Saharan Africa (table 3). Renal tumours were common in children aged 0–4 years (11 297 [8·9%] 
of 127 096), and their relative frequency decreased in older age groups, to 0·7% (756 of 100 860) in 
young people aged 15–19 years (figure 2). Bone tumours constituted 4·7% (13 320 of 284 649) of 
all cancers in children aged 0–14 years, and 7·8% (7851 of 100 860) in those aged 15–19 years 
(figure 2; appendix p 10). Soft tissue sarcomas were present in a similar proportion of cases in 
children aged 0–14 years and those aged 15–19 years in most regions (table 3, 4; figure 2; appendix 
p 10). In sub-Saharan Africa, 46% (579 of 1262) of all soft tissue sarcomas in children aged 0–14 
years were Kaposi's sarcoma compared with 57% (119 of 208) in those aged 0–19 years, whereas in 
all the other regions Kaposi's sarcoma represented less than 1% of all soft tissue sarcomas in 
children younger than 15 years and a maximum of 2% (14 of 592) in black children in the USA 
(data for all regions not shown). Germ cell and gonadal tumours were rare in children younger than 
15 years (10 200 [3·6%] of 284 649; table 3), and more common in those aged 15–19 years (12 105 
[12·0%] of 100 860; table 4). The group of epithelial neoplasms and melanoma comprises several 
specific types of carcinomas (adrenocortical, thyroid, nasopharyngeal, skin), all other types of 
carcinoma (except those occurring in kidney, liver, and gonads), and melanoma. This group 
constituted 3·8% (10 679 of 284 649) of all tumours in children aged 0–14 years and 21·3% (21 480 
of 100 860) in those aged 15–19 years (appendix p 10). The group of other and unspecified tumours 
comprised 0·9% (2469 of 284 649) of all cases in children aged 0–14 years and 1·5% (1500 of 
100 860) of all cases in those aged 15–19 years. In 22 registries no tumours were classified in this 
category; other and unspecified tumours comprised 5% or more of all tumours in ten registries, 
including one registry for which 12% (68 of 561) of all tumours were classified as other and 
unspecified. 
In children aged 0–14 years, the leading cancers in all regions combined were leukaemia, followed 
by CNS tumours, and then lymphomas, and this ranking was observed in most world regions (table 
3). The exception to this pattern was seen in the two African regions (appendix p 10). Incidence 
rates of all tumour types varied considerably between the regions (figure 3). The ratios of highest to 
lowest regional WSR were higher than 5·0 for CNS tumours (6·2), germ cell and gonadal tumours 
(5·9), neuroblastoma (5·6), epithelial tumours and melanoma (5·5), and leukaemia (5·2). 
In young people aged 15–19 years, lymphomas were the most common cancers in all regions 
combined, followed by epithelial tumours and melanoma (table 4; figure 4). However, leukaemia 
was the most common neoplasm in this age group in South America, Native American and white 
Hispanic children in the USA, south Asia (India), and southeast Asia (table 4; figure 4). In Oceania, 
white non-Hispanic children in the USA, in east Asia, and in Central America and the Caribbean the 
most common cancer type was the group of epithelial cancers and melanoma (table 4; figure 4). 
Geographical variations in incidence, expressed as the ratio of the highest to the lowest ASR across 
regions, were 5·0 or higher for hepatic tumours (7·8), germ cell tumours (6·4), CNS tumours (6·0), 
lymphomas (5·4), epithelial tumours and melanoma (5·2), and soft tissue sarcomas (5·0). 
From the 1980s to 2001–10, the overall WSR for all tumours in children aged 0–14 years increased 
from 124·0 per million person-years (95% CI 123·3–124·7) in the 1980s to 140·6 per million 
person-years (140·1–141·1) in 2001–10. The increase was seen in all regions except sub-Saharan 
Africa, and was smallest in Central America and the Caribbean (WSR 125·3 [95% CI 121·2–129·4] 
in 1980–89; 129·2 [95% CI 125·9–132·5] in 2001–10) and highest in southeast Asia (92·0 [95% CI 
89·2–94·8]; 119·8 [95% CI 117·3–122·3]). In sub-Saharan Africa, a decrease was noted between 
the 1980s (81·0 [95% CI 76·8–85·2]) and 2001–10 (56·3 [95% CI 55·1–57·5]; figure 5; appendix p 
7). 
Discussion 
Using data provided by 153 high-quality cancer registries, we report internationally comparable 
incidence rates of cancer in children aged 0–19 years during 2001–10. The incidence of cancer in 
children aged 0–14 years was 140·6 per million person-years, and in those aged 0–19 years was 
155·8 per million person-years. We report considerable variations in incidence by diagnostic 
group,6 sex, age group, and world region. We have also shown that the overall WSR in children 
aged 0–14 years has increased between the preceding comparable publication covering the 1980s,10 
and 2001–10. To our knowledge, this report presents the best available information on cancer 
incidence for the given period and age group. 
We chose WSR as a relative estimate of cancer burden, but it should not be used for estimating 
numbers of cases in a population, because the value of WSR depends on the choice of the standard 
population. The world standard population7 has been used in previous international publications;1, 2 
choosing the same standard thus ensures comparability between populations and periods. 
Although 20% of the cancers occurring in young people aged 15–19 years were epithelial tumours 
(the most prevalent histology types in adults) or melanoma, this age group also had high 
proportions of lymphomas, leukaemias, germ cell tumours, and sarcomas. Therefore, ICCC-36 
seems to be well adapted to reporting incidence in this age group, because the named tumour groups 
represent the main diagnostic categories in ICCC-3. We found that the incidence of cancer in young 
people aged 15–19 years was 185·3 per million person-years, based on 100 860 cases. 
Because not all the contributing paediatric cancer registries could provide data for young people 
aged 15–19 years, the analyses for children aged 0–14 years were based on a different dataset 
(paediatric dataset) than were the analyses for children aged 0–19 years or those aged 15–19 years 
(general dataset). The two resulting datasets gave different estimates of incidence for the (common) 
age group of 0–14 years, and this incidence was 5% lower in the paediatric than in the general 
dataset. This difference can be explained by variations in population coverage between the 
registries, and possibly distinctive data sources used by the two types of registries (ie, those that 
included data for young people aged 15–19 years and those that did not), as was shown previously 
in an analysis of data on childhood cancer in Europe.4 Although the results presented from both 
datasets are based on the best data available for each age group, they also emphasise the importance 
of quality assurance, particularly when dealing with a rare disease such as childhood cancer. 
We selected the contributing registries because they provided quality-assured data for the entire 
decade of 2001–10. Inevitably, the reported rates were influenced by this selection; however, they 
provide the best and unique comparable global incidence estimates for the given period because 
they are not affected by intermittent contributions for parts of the target period. 
A particular strength of our study comes from separate presentation of the incidence patterns for the 
five racial and ethnic groups distinguished in the US data, despite the difficulties in classifying the 
US population into racial and ethnic groups due to population mixing, migration, and self-
declaration of ethnicity.11 Unfortunately, the ethnic differences within multi-ethnic populations of 
Europe, Canada, and some other regions could not be readily studied. In other countries (South 
Africa, Israel, Australia) it was possible to gather incidence data for specific ethnicities within the 
population. For the purpose of simplicity these data were not included in this paper; however, they 
are available online on the IICC-3 website. 
Our study improved the overall data quality in all participating cancer registries, particularly in 72 
of 153 whose datasets were not acceptable at the beginning of the study. The study raised the 
registries' awareness of additional data sources (haematology, opthalmology, orthopaedics, 
dermatologicaly, neurology, endocrinology, and paediatric clinics) and of specific quality control. 
We required a high level of quality and completeness for our study, because small errors or 
omissions would have had a large impact on the resulting incidence rates. 
Approximately 30 cancer registries dropped out of the study, irrespective of the quality of their 
data. Such loss is especially regrettable in LMICs, where data are sparse and health policy has to be 
based on information from other countries. Data collected on more than 40 million person-years in 
12 cancer registries (Canada [New Brunswick, Prince Edward Island], Denmark, Finland, Germany 
[Berlin, Brandenburg, Bremen, Mecklenburg-Vorpommern, Sachsen-Anhalt, and the Free States 
Saxony and Thuringia], and Singapore) could not be used because these registries were bound by 
requirements of a specific administrative procedure to approve provision of their data. 
Although the cancer registries follow international guidelines, we observed wide variation in 
registration techniques, access to data sources, case eligibility criteria, application and interpretation 
of registration standards, and coding systems. Non-malignant tumours represented 0–10% of the 
total cases and affected international comparability. Non-malignant tumours were eligible for 
registration more commonly in Europe than in other parts of the world. Other practices reduced data 
quality (eg, restricted or no access to pathology reports), completeness (eg, restricted or no access to 
identifiable death certificates), or timeliness (eg, third-party data encryption). In some registries 
cases were coded as microscopically verified only if the pathology report could be reviewed by 
registry staff. In others, precise morphology codes were not available for a large proportion of 
microscopically verified diagnoses. Registries are often under-resourced, and large investments for 
a small proportion of cases in general cancer registries might not be seen as a priority; however, 
these variations highlight the need for support to enable production of high-quality and comparable 
data. 
A high proportion of specified diagnoses cannot be ensured without available specialised diagnostic 
facilities. The category of unspecified morphology might have included misclassified specific 
cancers, but in the absence of precise documentation it might have also included cases that were not 
malignant or cancers that did not occur in children. 
Although the differences in sex ratios by diagnostic group and age might have to a large extent 
reflected true differences in disease occurrence,12 the differences by geographical region could have 
more readily reflected sociocultural customs whereby boys are favoured over girls to seek medical 
attention when sick. The potential for such selective treatment in India and in some African 
populations was supported by our registry contacts in those regions when we inquired about a 
possibility of inequality in seeking health care. 
The registries with no access to a national database of all causes of death might not have registered 
the cancers that were only discovered at the time of death, even though the proportion of missed 
cases might be low in childhood populations. In some countries death certification is non-existent 
whereas in others access to these records is hindered by data protection laws. 
Factors external to the registry operations should also be considered. Higher socioeconomic level of 
development, better treatment facilities, and unobstructed access to data sources are linked to more 
advanced registration systems and better data quality. The registries operating in some LMICs were 
particularly affected by missing or infrequent official population estimates, and these data needed to 
be estimated by interpolation or extrapolation, influencing the reported rates. The low incidence 
rates observed in low-resource regions might in part have resulted from underdiagnosis,13 but our 
analysis could not quantify its extent. Treatment abandonment, common in LMICs,14 might also 
have led to under-registration if identified patients who refused treatment were not sufficiently well 
described (eg, missing dates or place of residence). Under-ascertainment of diagnosed cases might 
have resulted from administrative restrictions of access to medical files, political or social 
instability, competing needs, and inadequate political will, causing a dearth of resources, shortage 
or volatility of registry personnel, loss of perennial expertise, and missing or broken links with 
relevant data sources. Overestimates of incidence might have occurred in areas with superior 
treatment facilities if the place of permanent residence could not be correctly determined for 
registered patients, and national coverage would neutralise such artefactual regional differences 
within a country.15 Accurate incidence rates are also difficult to obtain in ethnic minorities, such as 
the Native American population in the USA, possibly because of imprecise classification of the at-
risk population, as well as patients with cancer.16 Cancer statistics in high-income countries might 
be influenced by overdiagnosis of some cancers detected by non-invasive imaging and screening 
tests, including neuroblastoma, thyroid cancer, melanoma, and kidney cancer.17 
Although a complete assessment of time trends in incidence falls outside the scope of this report, 
our data showed that the overall incidence of registered neoplasms in childhood increased between 
the 1980s and the 2000s. Our comparison is certainly influenced by the composition of the two data 
pools (different registries have contributed to the two compared periods); however, the increase in 
the overall rates is clear. The reasons might include improved diagnosis (eg, imaging of brain 
tumours in high-income countries and less underdiagnosis in some parts of world). Cancer 
registration is also developing constantly, and more effective ascertainment techniques might have 
been used since the 1980s. Future detailed analyses of time trends by tumour group and 
subpopulations will bring more clarity to the interpretation of these secular changes. 
The reduction of cancer incidence in sub-Saharan Africa probably had two main causes. First, this 
IICC-3 study included data from the national childhood cancer registry of South Africa, which 
contributed 70% of all cases for this region and reported very low incidence rates. Of the five 
datasets classified as sub-Saharan African in IICC-2, only one (from Namibia) reported a lower 
overall incidence rate than the South African registry in IICC-3. The possible reasons for the low 
rates in South Africa are discussed elsewhere.18 Second, the implementation of antiretroviral 
therapy in some areas affected by HIV19 has contributed to a decrease in incidence of Kaposi's 
sarcoma. This cancer type represented more than a third of the total cancer incidence in Kampala, 
Uganda, in the IICC-2 (WSR 182·7 per million person-years). The incidence of Kaposi's sarcoma in 
Kampala halved between the IICC-2 and this IICC-3 study, and a decreasing trend between the 
1990s and the 2000s was also noted in a Kampala registry study.20 
Leukaemia, the most common cancer in children worldwide, had the largest impact on total cancer 
incidence. The strikingly low incidence of leukaemia in the African regions, notably in sub-Saharan 
Africa, might give some clues as to the cause of this cancer. Even though strong underdiagnosis of 
leukaemia is suspected in sub-Saharan Africa,21 leukaemia was also less commonly diagnosed in 
black children in the USA than in the other US ethnic groups; however, whether leukaemia might 
be underdiagnosed as a result of reduced access to health care associated with lower economic 
status in this group is unclear.22 In children aged 0–14 years, the highest leukaemia rates were in 
Hispanic white children in the USA (40% of total incidence). The Native American component of 
Hispanic ancestry was a presumed risk factor, based on the observations that known risk alleles at 
loci identified in genome-wide association studies of European-ancestry populations in CDKN2A, 
PIP4K2A, CEBPE, and ARID5B were all significantly associated with Native American ancestry.23 
Comparatively high incidence rates and the largest proportion of leukaemia among all cancers were 
reported in southeast Asia. A link to the massive use of pesticides in this world region24 to protect 
crops and increase yields should be examined in specific studies, since exposure to pesticides has 
been associated with leukaemia risk.25, 26 
The male predominance among patients with lymphoma is probably a result of innate sex 
differences in susceptibility, but with increasing age other factors might play a role, such as the 
increased risk of HIV infection in boys compared with girls.27 The highest incidence of lymphomas 
worldwide has been reported in the Mediterranean region (as shown in our study and others28), and 
in HIV-infected populations,29 with B-cell non-Hodgkin lymphoma an AIDS-defining malignancy. 
Burkitt's lymphoma is endemic and common in some sub-Saharan African childhood populations,30 
in which HIV infection can further accentuate its incidence.2, 31 Hodgkin's lymphoma is rarer in 
populations of south and east Asia than in other parts of the world; the undergoing socioeconomic 
changes might gradually result in a similarly high incidence to that observed in Western 
populations.32, 33 
The highest incidence of all CNS tumours was noted in high-income countries, which is clearly 
related to the wide availability of diagnostic facilities. The lower incidence rates in LMICs most 
probably (and proportionately) reflect poor access to neuroimaging facilities (eg, low number of CT 
or MRI scans, long waiting lists, and prohibitive costs of diagnostics tests).34, 35 This poor access 
causes delay in diagnosis and possibly underdiagnosis of brain tumours.36 Comparability of 
incidence of CNS tumours across the continents would be greatly improved if all registries 
attempted to collect information on non-malignant CNS tumours, at least in children. 
This study describes the global cancer incidence patterns in children younger than 20 years for 
2001–10, providing an update to comparable information that is now almost 20 years old.2 Despite 
possible artefacts influencing data availability, quality, and comparability, the size of the studied 
populations and the observed differences in our study suggest that our data are sufficiently robust 
for international comparisons of childhood cancer occurrence, and provide useful pointers for 
further studies. The collected data can be used for further research, including continued 
development of childhood-specific registration standards and guidelines, detailed studies in 
subpopulations and by tumour subtype, and global estimates of cancer indicators. This report 
constitutes a springboard for attaining several targets of the Sustainable Development Goal aiming 
at ensuring healthy lives and promoting wellbeing of all at all ages. High-quality data over time is 
vital to devising cancer control mechanisms in childhood populations worldwide. Local data that 
are internationally comparable are therefore indispensable for aetiological research and for effective 
health policy actions. Sharing of data internationally should not impose an unaffordable burden on 
data acquisition and validation in coordinated studies. To secure data availability and quality, 
constant support of cancer registration is required at local, national, and international levels. 
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